Freenome
Founded Year
2014Stage
Series F | AliveTotal Raised
$1.353BLast Raised
$254M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-105 points in the past 30 days
About Freenome
Freenome focuses on early cancer detection through blood tests. The company's main offerings include next-generation blood tests that utilize multiomics technology and machine learning to identify cancer in its early stages. Freenome primarily serves the healthcare sector with a focus on improving cancer screening and detection. It was founded in 2014 and is based in Brisbane, California.
Loading...
ESPs containing Freenome
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…
Freenome named as Challenger among 15 other companies, including Exact Sciences, QIAGEN, and Veracyte.
Loading...
Research containing Freenome
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Freenome in 9 CB Insights research briefs, most recently on Jan 16, 2025.
Jan 16, 2025 report
State of Digital Health 2024 Report
Apr 25, 2024 report
State of Digital Health Q1’24 Report
Apr 4, 2024 report
State of Venture Q1’24 Report
Aug 10, 2023
The oncology tech market map
Aug 1, 2023
The state of healthcare AI in 5 charts
Expert Collections containing Freenome
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Freenome is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,270 items
AI 100
99 items
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
Conference Exhibitors
5,501 items
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,305 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Freenome Patents
Freenome has filed 22 patents.
The 3 most popular patent topics include:
- molecular biology
- genetics
- microrna
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/18/2023 | 3/11/2025 | Clusters of differentiation, Blood tests, Blood, Human cells, Immunology | Grant |
Application Date | 8/18/2023 |
|---|---|
Grant Date | 3/11/2025 |
Title | |
Related Topics | Clusters of differentiation, Blood tests, Blood, Human cells, Immunology |
Status | Grant |
Latest Freenome News
Apr 9, 2025
APR 08, 2025 | 5:08 PM PDT | BIOCENTURY | MANAGEMENT TRACKSAS ROCKET AWAITS FDA REVIEW, J&J VET CHAUDHURI JOINS AS COMMERCIAL LEADBY Plus: C-suite changes at Freenome, Telix, Trex Bio, Myricx, General Oncology, Bostongene and Acrivonhttps://www.biocentury.com/article/655574/as-rocket-awaits-fda-review-j-j-vet-chaudhuri-joins-as-commercial-lead© 2025 BioCentury Inc. All Rights Reserved
Freenome Frequently Asked Questions (FAQ)
When was Freenome founded?
Freenome was founded in 2014.
Where is Freenome's headquarters?
Freenome's headquarters is located at 3300 Marina Boulevard, Brisbane.
What is Freenome's latest funding round?
Freenome's latest funding round is Series F.
How much did Freenome raise?
Freenome raised a total of $1.353B.
Who are the investors of Freenome?
Investors of Freenome include Andreessen Horowitz, DCVC, Perceptive Advisors, T. Rowe Price, Section 32 and 49 more.
Who are Freenome's competitors?
Competitors of Freenome include Owlstone Medical, 20/20 GeneSystems, BioTwin, GRAIL, Diagu and 7 more.
Loading...
Compare Freenome to Competitors
20/20 GeneSystems focuses on cancer screening and diagnostic testing within the life sciences sector. The company offers diagnostic tests including OneTest for Cancer, which analyzes cancer biomarkers from a single blood sample, and CoronaCheck, which provides viral testing services. It serves the healthcare industry with its diagnostic tests. It was founded in 2000 and is based in Gaithersburg, Maryland.
Owlstone Medical focuses on breath analysis for disease detection within the healthcare sector. The company develops technology for discovering and validating biomarkers in breath, employing chemical analysis and sensor technology for diagnosis. Owlstone Medical's products and services are intended for academic, clinical, and pharmaceutical research partners involved in developing breath-based diagnostics. It was founded in 2004 and is based in Cambridge, United Kingdom.
OncoTAb specializes in biotechnology with a focus on cancer diagnostic solutions. The company offers Agkura® Personal Score, a non-invasive blood test that measures tumor protein levels to aid in breast cancer detection. This test serves as a supplemental tool to mammography, which often misses cancers in women with dense breast tissue. It is based in Charlotte, North Carolina.
AccuraGen develops liquid biopsy technology for the cancer diagnostics industry. The company provides services related to DNA and RNA sequencing to assist in treatment plans for cancer patients, emphasizing non-invasive diagnostic methods. AccuraGen serves the healthcare sector, particularly in oncology. It is based in Menlo Park, California.
Liquid Genomics provides testing services for the detection of cancer gene mutations through blood-based testing within the healthcare and biotechnology sectors. The company utilizes digital PCR and allele-specific blocker PCR technologies to identify and quantify mutations in blood or tissue samples. Its services are aimed at the healthcare industry, focusing on cancer diagnostics and research. It is based in Torrance, California.
Artificial Intelligence Expert focuses on AI technologies related to early detection of cancer within the healthcare sector. The company provides tests that can identify various types of cancer with reported accuracy rates. It is based in Cluj-Napoca, Romania.
Loading...